180-Day Exclusivity: What is Past is Prologue
Monday, October 2, 2023
11:15 a.m. - 12:15 p.m.
The critical role that 180-day exclusivity plays in accelerating patient access to generic medicines continues to be misunderstood by policymakers, journalists, and other stakeholders in Washington. This session will explore subjects such as the complex history of 180-day exclusivity, and the potential impact of recent reform proposals.
Speakers:
Chad Landmon, J.D.
Partner, Axinn, Veltrop & Harkrider LLP
Brian McCormick, J.D., M.H.S.
Vice President and Chief Regulatory Counsel, Teva Pharmaceuticals
Moderator:
Kurt Karst, J.D.
Director, Hyman, Phelps & McNamara
